Newstrail.com

Search

Amyotrophic Lateral Sclerosis (ALS) Treatment Market will Reach $762.3 Million by 2027

Amyotrophic Lateral Sclerosis (ALS) Treatment Market will Reach $762.3 Million by 2027

Highlighted with 80 tables and 67 figures, this 139-page report “Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.

Global amyotrophic lateral sclerosis treatment market will reach $762.3 million by 2027, growing by 5.8% annually over 2020-2027 owing to the increasing geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies.

The Amyotrophic Lateral Sclerosis (ALS) Treatment Market report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year.

Request Research Sample with Latest Industry Insights: https://altusmarketresearch.com/reports/sample/3395

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Region.

Based on Treatment Type, the global Amyotrophic Lateral Sclerosis (ALS) Treatment Market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.

• Medication
o Riluzole (Rilutek)
o Radicava (Edaravone)
o Tiglutik (Thickened Riluzole)
o Nuedexta
• Stem Cell Therapy
• Other Treatments

Based on ALS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.

• Sporadic ALS
• Familial ALS

Based on Distribution Channel, the global Amyotrophic Lateral Sclerosis (ALS) Treatment Market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

Geographically, the following regions together with the listed national/local markets are fully investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Key Players 

AB Science SA
Amylyx Pharmaceuticals Inc.
Biogen Inc.
Biohaven Pharmaceutical Holding Co., Ltd.
BrainStorm Cell Limited
Corestem, Inc.
F.Hoffmann-La Roche AG
Ionis Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.

Facebook
Twitter
LinkedIn
Pinterest